Pharma BD Deal Intelligence
Rigel Pharmaceuticals entered a license agreement with Arvinas and Pfizer for the exclusive global development, manufacturing and commercialization rights to VEPPANU (vepdegestrant). Arvinas and Pfizer will receive $70 million upfront plus $15 million upon transition completion, with up to $320 million in development, regulatory and commercial milestones plus tiered royalties in the mid-teens to mid-20s, split evenly between Arvinas and Pfizer. Rigel will launch in the U.S. and owns global rights. The transaction is expected to close in mid-June 2026, subject to customary closing conditions including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act; VEPPANU will become Rigel's fourth commercial product upon closing. As of early June 2026 the deal remains pending (not yet closed).